Space Drugs: First Major Pharma Invests in Orbit Manufacturing

Making medicines in space just became a real business, not just a NASA experiment.

United Therapeutics Corporation announced this week it will partner with space startup Varda Space Industries to develop improved treatments for rare lung diseases in orbit. This marks the first time a major pharmaceutical company has used its own funds, rather than NASA grants, to manufacture products in microgravity.

The partnership builds on decades of NASA research showing that molecules behave differently without gravity. In space, drug molecules assemble more slowly and uniformly, creating better crystalline structures. This seemingly small change can make medications dissolve more consistently, last longer on shelves, and reduce side effects for patients.

The breakthrough became possible thanks to Varda's innovative approach. The company launches small, uncrewed capsules equipped with autonomous bioreactors that process pharmaceuticals in space for weeks or months, then return to Earth. Since mid-2023, Varda has launched six of these vehicles.

"This is a really good historical moment for the space industry," said Delian Asparouhov, Varda's president and co-founder. His company plans to launch three more missions this year and seven next year.

The timing couldn't be better. Reusable rockets from SpaceX have dramatically reduced launch costs and increased flight frequency. Varda's spacecraft hitch rides on SpaceX's Transporter missions, which carry dozens of payloads at once.

The Ripple Effect

The implications extend far beyond one partnership. Scientists have already demonstrated success stories, like growing a better crystalline form of the cancer drug Keytruda in 2019. That breakthrough meant patients could receive injections instead of spending hours in clinics for intravenous treatments.

Varda now operates a 10,000-square-foot pharmaceutical lab in El Segundo, California, where researchers screen potential applications before sending the most promising candidates to space. The company employs about 200 people and has raised $330 million.

Asparouhov sees gravity as just another variable that manufacturers can adjust, like temperature or pressure, to improve their products. His long-term vision isn't to be a space company at all, but a pharmaceutical company that happens to operate in orbit.

The shift from government-funded research to commercial investment signals that orbital manufacturing has crossed a crucial threshold. When pharmaceutical companies start spending their own money on space production, it means they see real value in what microgravity can deliver.

More companies are likely to follow United Therapeutics into orbit, turning what once seemed like science fiction into standard pharmaceutical practice.